KD Pharma (Bexbach, Germany) is now officially launching the ingredient, KD Active, for the sports nutrition market.
Photo © iStockphoto.com/GlobalStock
Following a 2014 study showing that a high-concentrate omega-3 supplement may help alleviate delayed onset muscle soreness in young adults, KD Pharma (Bexbach, Germany) is now officially launching the ingredient, KD Active, for the sports nutrition market.
“KD Active is a 90% total omega-3 fish oil concentrate, bringing the same 3:2 EPA:DHA ratio found in starting fish,” said Nico Bonne, director of business development, North America, KD Pharma, in a press release. “The concentrate doesn’t, however, contain unhealthy ingredients like cholesterol, saturated fats, monounsaturated fats, and omega-6.”
The company attributes its high-concentrate quality to its patented supercritical fluid process that gently extracts and purifies polyunsaturated fatty acids, enabling concentrates with purity up to 99%.
Unlike acute muscle soreness, which happens shortly after exercising, delayed onset muscle soreness (DOMS) is pain and stiffness that sets in later, usually 24 to 48 hours post-exercise, and can last for up to a week. DOMS often occurs after eccentric (muscle lengthening) exercise.
In the 2014 Journal of Sports Science and Medicine study1, 69 subjects took either a placebo or 2.7 g of KD Pharma’s EPA+DHA supplement daily for 30 days prior to physical exercise testing in order to raise tissue levels of omega-3 (the Omega-3 Index) in the intervention group. At 30 days, subjects performed an eccentric exercise routine-multiple sets of maximum eccentric forearm extensions to induce muscle soreness-and were measured at baseline and at 24, 48, 72, and 96 hours post-exercise for markers such as C-reactive protein (CRP), creatine kinase, blood lactate levels, and functional measurements of DOMS, including indirect markers of soreness such as arm extension and torque and flexibility.
At 72 and 96 hours post-exercise, omega-3–supplemented subjects, when evaluated on functional markers of DOMS, exhibited less DOMS pain compared to placebo subjects. There was also a significant difference in blood lactate levels between the two groups (elevated blood lactate levels can impact endurance performance), with the omega-3 subjects showing lower levels of blood lactate as well as CRP. Omega-3 subjects also self-reported a higher quality of life and less DOMS pain via the Profile of Mood States Questionnaire.
Researchers found no significant difference in creatine kinase levels or in extension or strength between the two groups, however.
According to researchers, “Reduced pain in the higher N3 Index Group may be due to an increased concentration of omega-3 fatty acids in the muscle cell walls, thus triggering a higher elasticity, flexibility, and lower risk of physical damage to muscle tissue during exercise.” They added, “These findings support the hypothesis that higher omega-3 tissue levels may have a protective effect on muscle cells during exercise and may act by reducing the inflammatory response and subsequent DOMS.”
Jennifer Grebow
Editor-in-Chief
Nutritional Outlook magazine
jennifer.grebow@ubm.com
Rousselot to showcase new collagen peptide research and targeted solutions at Vitafoods Europe 2024
April 25th 2024The company will be highlighting new research that demonstrates the ability of its Peptan collagen peptide brand to support sleep quality, reduce gastrointestinal discomfort, and enhance skin health, including density, hydration, and elasticity.
Judge denies CRN’s motion for preliminary injunction but its lawsuit against NY state will proceed
April 23rd 2024The judge in CRN's lawsuit against NY state's law banning the sale of weight management and muscle building supplements to minors has denied its motion for a preliminary injunction, but determined that CRN has standing to sue on behalf of its members.
Arla Foods to acquired whey nutrition business from Volac International
April 22nd 2024Arla Foods Ingredients has reached an agreement to acquire Volac’s Whey Nutrition business through a purchase of shares in Volac Whey Nutrition Holdings Limited and its subsidiary, Volac Whey Nutrition Limited and Volac Renewable Energy Limited.
Rousselot to showcase new collagen peptide research and targeted solutions at Vitafoods Europe 2024
April 25th 2024The company will be highlighting new research that demonstrates the ability of its Peptan collagen peptide brand to support sleep quality, reduce gastrointestinal discomfort, and enhance skin health, including density, hydration, and elasticity.
Judge denies CRN’s motion for preliminary injunction but its lawsuit against NY state will proceed
April 23rd 2024The judge in CRN's lawsuit against NY state's law banning the sale of weight management and muscle building supplements to minors has denied its motion for a preliminary injunction, but determined that CRN has standing to sue on behalf of its members.
Arla Foods to acquired whey nutrition business from Volac International
April 22nd 2024Arla Foods Ingredients has reached an agreement to acquire Volac’s Whey Nutrition business through a purchase of shares in Volac Whey Nutrition Holdings Limited and its subsidiary, Volac Whey Nutrition Limited and Volac Renewable Energy Limited.
2 Commerce Drive
Cranbury, NJ 08512